On Wednesday, Shares of Pfizer Inc. (NYSE:PFE), lost -0.74% to $33.53.
Merck KGaA, Darmstadt, Germany, and Pfizer recently declared multiple presentations on studies evaluating the preliminary safety and efficacy of avelumab at the 2015 American Society of Clinical Oncology (ASCO) annual meeting.
Avelumab (also known as MSB0010718C) is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody. By inhibiting PD-L1 interactions, avelumab is thought to enable the activation of T-cells and the adaptive immune system. Further, by retaining a native Fc-region, avelumab is thought to engage the innate immune system and may induce antibody-dependent cell-mediated cytotoxicity (ADCC). In November, 2014, Merck KGaA, Darmstadt, Germany, and Pfizer declared a planned alliance to jointly develop and commercialize avelumab.
Avelumab presentations at ASCO provide the latest clinical updates accessible across various tumor types, counting an oral presentation on ovarian cancer and posters on gastric cancer, non-small cell lung cancer (NSCLC) and several other studies in a range of patient populations.
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments.
Shares of FuelCell Energy Inc. (NASDAQ:FCEL), declined -1.20% to $1.24, during its last trading session.
FuelCell Energy, declared that Natica von Althann has been designated to the Company’s Board of Directors. She brings with her extensive financial and risk administration expertise gained from senior executive roles at Bank of America and Citigroup in addition to utility experience gained from her six years as a member of the PPL Corporation board of directors, one of the largest investor-owned companies in the U.S. utility sector, with about 18,000 megawatts of power generating capacity. Ms. von Althann will serve on the FuelCell Energy Audit & Finance and Compensation committees. This addition to the FuelCell Energy Board of Directors enhances the total number of members to eight.
“Natica adds a new dynamic to our Board with her wealth of experience and knowledge of the utility industry, bank lending and global financial markets,” said Chip Bottone, Chief Executive Officer, FuelCell Energy, Inc. “We look forward to benefitting from her expertise as we work to develop larger power generation projects that deliver affordable and ultra-clean power.”
“FuelCell Energy is well-positioned with a distributed power generation solution that meets the needs of power users and within an environmental profile that benefits society at large,” said Ms. Von Althann. “I am eager to start working with the Board to support and enable further growth of FuelCell Energy.”
FuelCell Energy, Inc., together its auxiliaries, designs, manufactures, sells, installs, operates, and services stationary fuel cell power plants for distributed power generation. The company is also involved in the development, design, production, and sale of fuel cell products under the Direct FuelCell name.
At the end of Wednesday’s trade, Shares of Celgene Corporation (NASDAQ:CELG), lost -0.16% to $113.40.
Celgene Corporation, declared more than 55 presentations reporting on investigational studies in blood and solid tumor cancers will be presented during the 51st American Society of Clinical Oncology meeting in Chicago, Ill. from May 30 to June 2, 2015.
Investigational data comprise:
- #1032 Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial – Poster – 8 a.m., Saturday, May 30, S Hall A
- #8523 Updated analysis of CALGB/ECOG/BMT CTN 100104: Lenalidomide (Len) vs. placebo (PBO) maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM).– Poster – 8 a.m., Sunday, May 31, S Hall A
- #8524 FIRST study: Updated overall survival (OS) in stem cell transplant (SCT)-ineligible newly diagnosed multiple myeloma (NDMM) patients (pts) treated with continuous lenalidomide plus low-dose dexamethasone (Rd) vs melphalan, prednisone, and thalidomide (MPT)– Poster- 8 a.m., Sunday, May 31, S Hall A
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID for the treatment of multiple myeloma; and VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, in addition to acute myeloid leukemia (AML).
Finally, Rowan Companies plc (NYSE:RDC), ended its last trade with 0.84% gain, and closed at $23.93.
Rowan Companies, declared recently that its Board of Directors has declared a quarterly cash dividend of $0.10 per Class A Ordinary Share payable on May 26, 2015 to the shareholders of record at the close of business on May 12, 2015.
Rowan Companies plc provides offshore oil and gas contract drilling services. It operates a fleet of 30 self-elevating mobile offshore jack-up drilling units, in addition to 3 ultra-deepwater drill ships. The company operates in the United States Gulf of Mexico, the United Kingdom, and Norwegian sectors of the North Sea, the Middle East, West and North Africa, Southeast Asia, and Trinidad. Rowan Companies plc was founded in 1923 and is based in Houston, Texas.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
